Viewing Study NCT03013504

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 9:19 PM
Ignite Modification Date: 2026-01-29 @ 1:54 AM
Study NCT ID: NCT03013504
Status: COMPLETED
Last Update Posted: 2024-11-06
First Post: 2016-12-29
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in HER2+ Early Breast Cancer Patients
Sponsor: Prestige Biopharma Limited
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None HER2 Positive Breast Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None randomized View
None double-blind View
None parallel group View
None equivalence View
None multicentre View
None phase III View
None efficacy View
None safety View
None pharmacokinetics View
None HD201 View
None docetaxel View
None Herceptin View
None HER2 positive View
None breast cancer View
None early breast cancer View